Transarterial chemoembolization combined with autologous DC-CIK cells for the treatment of hepatocellular carcinoma of BCLC C-stage：a randomized controlled study
10.3969/j.issn.1008-794X.2015.05.018
- VernacularTitle:肝动脉化疗栓塞术联合自体DC蛳CIK细胞治疗BCLC C期肝癌的随机对照研究
- Author:
Li LIU
;
Jiaming ZHONG
;
Xiaoxia CHEN
;
Ning DING
;
Qijun QIAN
;
Zengqiang QU
- Publication Type:Journal Article
- Keywords:
hepatocellular carcinoma;
hepatic arterial chemoembolization;
DC-CIK;
immune function;
T lymphocyte subsets
- From:
Journal of Interventional Radiology
2015;(5):434-438
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of transarterial chemoembolization (TACE) combined with autologous DC-CIK cells in treating hepatocellular carcinoma(HCC) of BCLC C-stage. Methods A total of 60 cases with HCC in BCLC C-stage were randomly and equally divided into the study group (n=30) and the control group (n=30). TACE combined with autologous DC-CIK cells was employed in the patients of the study group, while only TACE was adopted in the patients of the control group. The immune function, six-month and one-year survival rates were determined, and the results were compared between the two groups. Results In the study group, the blood T lymphocyte subsets of CD3+CD8+ were significantly increased, while CD3+CD4+ were obviously decreased. When compared with the pretreatment levels, the differences were statistically significant (P<0.05). The six-month survival rate of the study group and the control group was 67.9% and 48.1% respectively (P<0.05), and the one-year survival rate of the study group and the control group was 53.6%and 29.6%respectively (P<0.05). Conclusion For the treatment of HCC in BCLC C-stage, the therapeutic effect of TACE combined with autologous DC-CIK cells is much better than that of pure TACE. Therefore, this therapy is an effective treatment for HCC in BCLC C-stage.
